All In Biotech

Drug Trial Radar · NCT07894341

A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials

A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 26, 2026

Primary completion

Aug 31, 2041

Study completion Jun 30, 2042

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, single-arm extension study to evaluate the safety and efficacy of long-term administration of Inpegsomatropin Injection in participants with Idiopathic Short Stature (ISS) who have completed Phase Ⅲ clinical trials. Upon completion of the Phase Ⅲ clinical study, participants may enter the extension-phase baseline assessment period after the participant and their guardian provide informed consent, based on the willingness of the participant and guardian as well as the investigator's comprehensive assessment of the benefit-risk profile for the participant's continued participation in this study. Participants who meet all inclusion criteria and do not meet any exclusion criteria will proceed to the extension-phase treatment period to receive continued treatment with Inpegsomatropin Injection. Upon completion of the treatment period, participants will enter the final-height follow-up period, during which growth and development status, medication exposure and safety will be followed up via outpatient visits. This study aims to observe the long-term safety and efficacy of the investigational product.

Conditions

  • Idiopathic Short Stature

Interventions

  • Inpegsomatropin InjectionDrug

    Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly,treatment is continued until participants reach near-adult height.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results.Time frame: Every 13 weeks during the first year, and then every 52 weeks (up to 16 years)

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Capital Institute of Pediatrics, Beijing (SHOUER)

    Beijing, China · Recruiting

  • Hunan Children's Hospital

    Changsha, China · Recruiting

  • Chengdu Women's and Children's Central Hospital

    Chengdu, China · Recruiting

  • West China Second University Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The Third Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Anhui Provincial Children's Hospital

    Hefei, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Jiaxing First Hospital

    Jiaxing, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Recruiting

  • Kunming Children's Hospital

    Kunming, China · Recruiting

  • Gansu Provincial Maternity and Child Care Hospital

    Lanzhou, China · Recruiting

  • Jiangxi Provincial Children's Hospital

    Nanchang, China · Recruiting

  • Nanjing Children's Hospital

    Nanjing, China · Recruiting

  • The Affiliated Women's and Children's Hospital of Ningbo University

    Ningbo, China · Recruiting

  • Children's Hospital of Shanghai

    Shanghai, China · Recruiting

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Shanghai Children's Medical Center

    Shanghai, China · Recruiting

  • Children's Hospital Affiliated to Soochow University

    Suzhou, China · Recruiting

  • The Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China · Recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Wuhan Children's Hospital

    Wuhan, China · Recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, China · Recruiting

  • Henan Children's Hospital Zhengzhou Children's Hospital

    Zhengzhou, China · Recruiting

  • Zhuzhou Central Hospital

    Zhuzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.